4DMedical Ltd (ASX: 4DX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
4DMedical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$238.74 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
391.37 million
Earnings per share
-0.087
Dividend per share
N/A
Year To Date Return
-15.38%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
4DMedical Ltd (ASX: 4DX)
Latest News
Share Gainers
5 top ASX shares that would have more than doubled your money in 2023
Healthcare Shares
Guess which ASX healthcare share is rocketing 67% on a US hospital deal
Share Gainers
In a sea of red, these ASX All Ords shares are leaping higher on Monday
Share Gainers
Why is the 4DMedical share price rocketing 20% on Wednesday?
Earnings Results
Why has the 4D Medical share price popped 7% in a month?
Healthcare Shares
Why is the 4DMedical share price exploding 40% today?
Healthcare Shares
40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods
Share Gainers
Why is the 4DMedical (ASX:4DX) share price rocketing 30% today?
Healthcare Shares
4DMedical (ASX:4DX) share price launches 19% on first commercial scans
Healthcare Shares
4DMedical (ASX:4DX) share price gains amid boss' confidence for FY22
Share Market News
ASX 200 falls, Metcash down, 4DMedical drops
Healthcare Shares
4DMedical (ASX:4DX) share price is lifting on its COVID-related technology
Frequently Asked Questions
-
No, 4DMedical does not pay dividends at this time.
-
4DMedical listed on the ASX on 7 August 2020.
4DX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About 4DMedical Ltd
4DMedical Ltd (ASX: 4DX) is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. It is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.
The technology uses existing imaging systems and allows X-ray images to be taken simultaneously from various angles. Using image-processing methods adapted from aerospace engineering, the motion of lung tissue can be measured. This allows ventilation to be calculated at each stage of the breath and at every location within the lung. These measurements are then visualized as a coloured heat map to help medical professionals accurately identify ventilation deficits.
The 4DMedical technology is patented in key jurisdictions, including the US and Australia. The company is aiming to secure a slice of the global lung imaging market. The US market alone was valued at more than $US30 billion in normal pre-COVID diagnostic conditions.
4DX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Apr 2024 | $0.61 | $0.01 | 1.65% | 273,207 | $0.61 | $0.63 | $0.60 |
| 22 Apr 2024 | $0.61 | $-0.01 | -1.64% | 130,806 | $0.61 | $0.62 | $0.60 |
| 19 Apr 2024 | $0.61 | $0.01 | 1.67% | 451,246 | $0.61 | $0.62 | $0.59 |
| 18 Apr 2024 | $0.60 | $0.03 | 5.26% | 330,842 | $0.58 | $0.61 | $0.57 |
| 17 Apr 2024 | $0.57 | $0.00 | 0.00% | 203,323 | $0.58 | $0.58 | $0.57 |
| 16 Apr 2024 | $0.57 | $-0.01 | -1.72% | 272,670 | $0.58 | $0.59 | $0.57 |
| 15 Apr 2024 | $0.58 | $-0.01 | -1.69% | 588,073 | $0.58 | $0.59 | $0.57 |
| 12 Apr 2024 | $0.59 | $-0.03 | -4.88% | 1,519,795 | $0.62 | $0.62 | $0.58 |
| 11 Apr 2024 | $0.62 | $0.00 | 0.00% | 308,546 | $0.62 | $0.63 | $0.61 |
| 10 Apr 2024 | $0.62 | $-0.01 | -1.60% | 266,955 | $0.63 | $0.63 | $0.62 |
| 09 Apr 2024 | $0.63 | $-0.01 | -1.57% | 510,366 | $0.64 | $0.64 | $0.62 |
| 08 Apr 2024 | $0.64 | $0.01 | 1.59% | 449,971 | $0.63 | $0.64 | $0.62 |
| 05 Apr 2024 | $0.63 | $-0.02 | -3.08% | 365,566 | $0.65 | $0.65 | $0.63 |
| 04 Apr 2024 | $0.65 | $0.03 | 4.80% | 420,549 | $0.63 | $0.66 | $0.63 |
| 03 Apr 2024 | $0.63 | $-0.02 | -3.10% | 224,243 | $0.65 | $0.65 | $0.63 |
| 02 Apr 2024 | $0.65 | $-0.01 | -1.54% | 573,650 | $0.64 | $0.66 | $0.63 |
| 28 Mar 2024 | $0.65 | $0.04 | 6.50% | 461,378 | $0.62 | $0.65 | $0.62 |
| 27 Mar 2024 | $0.62 | $0.00 | 0.00% | 385,252 | $0.63 | $0.64 | $0.61 |
| 26 Mar 2024 | $0.62 | $-0.02 | -3.17% | 560,146 | $0.64 | $0.65 | $0.62 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Mar 2024 | Lilian (Lil) Bianchi | Exercise | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Lilian (Lil) Bianchi | Buy | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Geraldine McGinty | Exercise | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Geraldine McGinty | Buy | 40,000 | $29,000 |
Exercise of options.
|
| 23 Jan 2024 | Geraldine McGinty | Issued | 40,000 | $31,600 |
Director remuneration.
|
| 23 Jan 2024 | Lilian (Lil) Bianchi | Issued | 40,000 | $31,600 |
Director remuneration.
|
| 03 Nov 2023 | Andreas Fouras | Issued | 1,306,100 | $607,336 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Andrew Livingston | Executive Director | Mar 2018 |
Mr John Livingston has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. John was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. John has considerable commercial experience with multiple listed companies.
|
| Dr Robert Alan Figlin | Non-Executive Director | Dec 2016 |
A nationally recognised leader in genitourinary and thoracic oncology in the United States, Robert's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments and furthers Cedars Sinai's tradition of compassionate patient care. He is Chair of the Medical Advisory Committee.
|
| Dr Andreas Fouras | Chief Executive OfficerManaging Director | Dec 2012 |
Dr Andreas Fouras' career in academic research has a foundation gained within studying experimental fluid dynamics. This research into wind tunnel quantification garnered recognition as a young leader in the scientific discipline of fluid dynamics,
developing a number of new approaches to the imaging of gas and liquid flow. He is a member of the Medical Advisory Committee. |
| Ms Lilian (Lil) Bianchi | Non-Executive DirectorNon-Executive Chairman | Dec 2019 |
Ms Lilian Bianchi is an experienced Non-Executive Director and Audit & Risk Chair with a focus on innovative companies operating in highly regulated environments including health, finance, and infrastructure. Her CEO and executive career brought commercial leadership and digital transformation to global listed corporates through to tech startups across US, Australia, India, Singapore, UK, and Europe. She has an international technology research background including programs in health and telecommunications. Her product expertise is in analytics, AI and SaaS where she took to market new products for diverse sectors including FinTech and Transport. Lilian is an independent director and is Chair of the Audit and Risk Committee.
|
| Mr Julian Bernard Kingsley Sutton | Non-Executive Director | Sep 2017 |
Mr Julian Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later worked for Towers Perrin to Brussels and London as an asset consultant before moving to Credit Suisse Asset Management and then Schroders Investment Management as a portfolio manager in their respective multi-manager teams. After twelve years in London, Julian returned to Australia and formed a sales and marketing business helping best in class international fund management companies establish a presence in the Australian market. Currently, Julian is responsible for the sales and marketing function of Brown Advisory in Australia.
|
| Dr Geraldine Bernadette McGinty | Non-Executive Director | Sep 2023 |
Dr McGinty became the first woman elected as Chair of the American College of Radiologys (ACR) board of Chancellors. Prior to this, Dr McGinty headed up the ACRs Commission on Economics. Her corporate governance experience includes serving on the Board of NextGen Healthcare (NASDAQ:NXGN), an Atlanta-based provider of software, services and analytical solutions to primary healthcare providers, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles. She has also been in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. In 2017, Dr McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019.
|
| Ms Naomi Lawrie | Company SecretaryGeneral Counsel | Apr 2023 |
-
|
| Naomi Lawrie | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Velocimetry Consulting Pty Ltd | 64,838,000 | 18.79% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd | 18,106,697 | 5.25% |
| HSBC Custody Nominees (Australia) Limited | 7,580,063 | 2.20% |
| Ryder Innovation Fund Lp | 6,290,475 | 1.82% |
| National Nominees Limited | 3,663,160 | 1.06% |
| J P Morgan Nominees Australia Pty Limited | 3,038,117 | 0.88% |
| HSBC Custody Nominees (Australia) Limited – A/C 2 | 2,884,390 | 0.84% |
| Alex Petrou & Christine Petrou | 2,484,471 | 0.72% |
| Mr Damen Diamantopoulos | 2,470,000 | 0.72% |
| Netwealth Investments Limited | 2,340,650 | 0.68% |
| Citicorp Nominees Pty Limited | 2,083,306 | 0.60% |
| Mrs Irene Wai-Ping Lee & Miss Yvonne Lee & Mr Wilson Lee | 1,841,379 | 0.53% |
| John Livingston Pty Ltd | 1,817,243 | 0.53% |
| Endless Smiles Pty Ltd | 1,500,000 | 0.43% |
| BNP Paribas Nominees Pty Ltd | 1,480,089 | 0.43% |
| Mr Dev Jayram | 1,433,262 | 0.42% |
| Wal Assets Pty Ltd | 1,411,487 | 0.41% |
| Chapter 5 Pty Ltd | 1,220,697 | 0.35% |
| Jianwen Xiao | 1,216,176 | 0.35% |
| AAX Pty Ltd | 1,200,000 | 0.35% |
